Beyond CpG-7909, several other TLR9 agonists are under clinical investigation for cancer therapy, including MGN1703 (Lefitolimod), IMO-2125 (Tilsotolimod), SD-101, and CMP-001. This evidence concerns the gene TLR9 and cancer.